[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-237705-105":53,"doc-detail-237705-en":126},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":119,"head_meta":121,"extra_data":123,"updated_unix":125},105,"en","the-endocannabinoid-system-as-an-emerging-target-of-pharmacotherapy","The Endocannabinoid System as an Emerging Target of Pharmacotherapy","","The identification of cannabinoid receptors and endogenous lipid ligands has accelerated research on the endocannabinoid system and its roles in health and disease. Selective cannabinoid receptor antagonists, inhibitors of endocannabinoid metabolism and transport, and genetically modified mice have enabled deeper mechanistic insights. Modulating endocannabinoid activity shows therapeutic potential across diverse disorders, including neuropsychiatric and movement conditions, pain, cancer, and cardiovascular and metabolic diseases. Advances in pharmacological strategies are discussed as candidate therapies for unmet clinical needs.",{"@graph":63,"@context":118},[64,80,101],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":51,"@type":70,"position":76},"https://docshare.wps.com/template/general/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/the-endocannabinoid-system-as-an-emerging-target-of-pharmacotherapy/237705/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/the-endocannabinoid-system-as-an-emerging-target-of-pharmacotherapy/237705.png","ImageObject",442,249,{"name":88,"@type":89},"Jiven","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/vnd.openxmlformats-officedocument.wordprocessingml.document","2026-09-20","2026-09-11",true,{"@type":98,"interactionType":99,"userInteractionCount":76},"InteractionCounter",{"@type":100},"ViewAction",{"@type":102,"mainEntity":103},"FAQPage",[104,110,114],{"name":105,"@type":106,"acceptedAnswer":107},"How has research on the endocannabinoid system expanded?","Question",{"text":108,"@type":109},"The discovery of cannabinoid receptors and endogenous lipid ligands triggered rapid growth of studies, supported by tools such as selective receptor antagonists, metabolic/transport inhibitors, and receptor- or enzyme-deficient mice.","Answer",{"name":111,"@type":106,"acceptedAnswer":112},"Why is modulating the endocannabinoid system considered therapeutically promising?",{"text":113,"@type":109},"Modulation influences multiple physiological functions and has therapeutic potential across a wide range of diseases, from mood and anxiety disorders and neuropathic pain to cancer and cardiovascular or metabolic conditions.",{"name":115,"@type":106,"acceptedAnswer":116},"What strategies may reduce psychoactive side effects in cannabinoid-based treatments?",{"text":117,"@type":109},"Therapeutic approaches that use CB1 receptor antagonists or indirectly enhance endocannabinoid actions (by blocking metabolism or transport) may avoid psychoactivity. Selective CB2 receptor agonists, which lack psychoactive properties, are also highlighted as another promising avenue.","https://schema.org",{"og:url":78,"og:type":120,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":122,"canonical":78},"index,follow",{"doc_id":124,"site_id":56},237705,1789114526,{"code":4,"msg":5,"data":127},{"doc_id":124,"user_id":128,"nickname":88,"user_avatar":129,"doc_module":9,"category_id":50,"category_name":51,"doc_title":59,"doc_description":61,"doc_content":130,"file_id":131,"file_url":132,"file_type":133,"file_size":134,"view_count":76,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":135,"language":136,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":61,"update_tm":125,"read_time":140},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","The Endocannabinoid System as an Emerging Target of Pharmacotherapy\n\u0013 HYPERLINK \"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2241751/\" \u0014http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2241751/\u0015\nPharmacol Rev. Author manuscript; available in PMC 2008 Feb 13.\nPublished in final edited form as:\n\u0013 HYPERLINK \"http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=16968947\" \\t \"pmc_ext\" \u0014Pharmacol Rev. 2006 Sep; 58(3): 389–462.\u0015\ndoi:  \u0013 HYPERLINK \"http://dx.doi.org/10.1124%2Fpr.58.3.2\" \\t \"pmc_ext\" \u001410.1124/pr.58.3.2\u0015\nPMCID: PMC2241751\nNIHMSID: NIHMS38123\n\u0013 HYPERLINK \"http://www.ncbi.nlm.nih.gov/pubmed/?term=PACHER%20P%5Bauth%5D\" \u0014PÁL PACHER\u0015, \u0013 HYPERLINK \"http://www.ncbi.nlm.nih.gov/pubmed/?term=B%26%23x000c1%3BTKAI%20S%5Bauth%5D\" \u0014SÁNDOR BÁTKAI\u0015, and \u0013 HYPERLINK \"http://www.ncbi.nlm.nih.gov/pubmed/?term=KUNOS%20G%5Bauth%5D\" \u0014GEORGE KUNOS\u0015\n\u0013 HYPERLINK \"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2241751/\" \u0014Author information ►\u0015 \u0013 HYPERLINK \"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2241751/\" \u0014Copyright and License information ►\u0015\nThe publisher's final edited version of this article is available free at \u0013 HYPERLINK \"http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=16968947\" \\t \"pmc_ext\" \u0014Pharmacol Rev\u0015\nSee other articles in PMC that \u0013 HYPERLINK \"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2241751/citedby/\" \u0014cite\u0015 the published article.\n\u0013 HYPERLINK \"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2241751/\" \\o \"Go to other sections in this page\" \u0014Go to:\u0015\nAbstract\nThe recent identification of cannabinoid receptors and their endogenous lipid ligands has triggered an exponential growth of studies exploring the endocannabinoid system and its regulatory functions in health and disease. Such studies have been greatly facilitated by the introduction of selective cannabinoid receptor antagonists and inhibitors of endocannabinoid metabolism and transport, as well as mice deficient in cannabinoid receptors or the endocannabinoid-degrading enzyme fatty acid amidohydrolase. In the past decade, the endocannabinoid system has been implicated in a growing number of physiological functions, both in the central and peripheral nervous systems and in peripheral organs. More importantly, modulating the activity of the endocannabinoid system turned out to hold therapeutic promise in a wide range of disparate diseases and pathological conditions, ranging from mood and anxiety disorders, movement disorders such as Parkinson’s and Huntington’s disease, neuropathic pain, multiple sclerosis and spinal cord injury, to cancer, atherosclerosis, myocardial infarction, stroke, hypertension, glaucoma, obesity/metabolic syndrome, and osteoporosis, to name just a few. An impediment to the development of cannabinoid medications has been the socially unacceptable psychoactive properties of plant-derived or synthetic agonists, mediated by CB1 receptors. However, this problem does not arise when the therapeutic aim is achieved by treatment with a CB1 receptor antagonist, such as in obesity, and may also be absent when the action of endocannabinoids is enhanced indirectly through blocking their metabolism or transport. The use of selective CB2receptor agonists, which lack psychoactive properties, could represent another promising avenue for certain conditions. The abuse potential of plant-derived cannabinoids may also be limited through the use of preparations with controlled composition and the careful selection of dose and route of administration. The growing number of preclinical studies and clinical trials with compounds that modulate the endocannabinoid system will probably result in novel therapeutic approaches in a number of diseases for which current treatments do not fully address the patients’ need. Here, we provide a comprehensive overview on the current state of knowledge of the endocannabinoid system as a target of pharmacotherapy.\n\u0013 HYPERLINK \"http://www.ncbi.nlm.nih.gov/pmc/articles","cbCaiv6ICl6Ssk7e","https://ap.wps.com/l/cbCaiv6ICl6Ssk7e","docx",583326,203,"English","# Abstract\n# I. Introduction","[{\"question\":\"How has research on the endocannabinoid system expanded?\",\"answer\":\"The discovery of cannabinoid receptors and endogenous lipid ligands triggered rapid growth of studies, supported by tools such as selective receptor antagonists, metabolic/transport inhibitors, and receptor- or enzyme-deficient mice.\"},{\"question\":\"Why is modulating the endocannabinoid system considered therapeutically promising?\",\"answer\":\"Modulation influences multiple physiological functions and has therapeutic potential across a wide range of diseases, from mood and anxiety disorders and neuropathic pain to cancer and cardiovascular or metabolic conditions.\"},{\"question\":\"What strategies may reduce psychoactive side effects in cannabinoid-based treatments?\",\"answer\":\"Therapeutic approaches that use CB1 receptor antagonists or indirectly enhance endocannabinoid actions (by blocking metabolism or transport) may avoid psychoactivity. Selective CB2 receptor agonists, which lack psychoactive properties, are also highlighted as another promising avenue.\"}]","The Endocannabinoid System as an Emerging Target of Pharmacotherapy | DOCX",71]